Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

Who Took Part

According to the abstract, 48 patients were involved.

The age groups tagged for this paper are children, teenagers, adults, middle-aged adults and older adults, both men and women.

Ninety patients (42 male and 48 female patients), ranging from 11 to 75 years of age, underwent transsphenoidal surgery for GH-secreting pituitary adenoma.

Patients in whom GKS was contraindicated were treated with conventional radiotherapy or by medical means.

How the Study Was Run

Preoperative and postoperative GH and insulin-like growth factor-I levels were measured, as was the postoperative GH level after the oral glucose tolerance test.

Tumor size, cavernous sinus (CS) invasion, and residual tumor were evaluated using magnetic resonance (MR) imaging.

Transsphenoidal microsurgery was performed, followed by adjuvant GKS when there was persistent biochemical evidence of GH hypersecretion with residual tumor detectable in the CS on MR imaging.

What Was Measured

Topics PubMed links to this paper include Adenoma, Combined Modality Therapy, Glucose Tolerance Test, Growth Hormone, Insulin-Like Growth Factor I, Microsurgery and Neoplasm, Residual.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 48 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Journal of neurosurgery), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.